38-502:BRAFTOVI/MEKTOVI Combination Therapy Specified Drug Use Survey(CRC)
Ontology highlight
ABSTRACT: Primary outcome(s): [Safety]Occurrence status of adverse drug reactions and infections, Occurrence status of adverse drug reactions corresponding to specified safety concerns, Factors that are considered to affect safety
Specified safety concerns: Cutaneous malignancies, palmar-plantar erythrodysaesthesia syndrome, eye disorders, cardiac dysfunction, hypertension, rhabdomyolysis, hepatic dysfunction, and haemorrhage
[Efficacy]Antitumor effect and overall survival (OS)
DISEASE(S): Unresectable Advanced Or Recurrent Braf-mutant Colorectal Cancer
PROVIDER: 2613085 | ecrin-mdr-crc |
REPOSITORIES: ECRIN MDR
ACCESS DATA